Lyell acquires worldwide rights from ICT to CAR T-cell therapy
US Phase I clinical trial data reveal dose-dependent activity of LYL273 in 12 patients.
Cytiva Navigating cell therapy WP 4
Eli Lilly keeps up ophthalmic gene therapy push with $475m MeiraGTx deal
FDA halts uniQure’s plans for Huntington’s disease gene therapy
Helex secures $3.5m to advance kidney disease therapies
Eli Lilly buys Adverum in eye disease gene therapy punt
Galapagos to shutter cell and gene therapy unit
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
Rocket ditches blood disorder gene therapy in ongoing pipeline pivot
